English 
The International Society for Cell and Gene Therapy together with the Japanese Society for Regenerative Medicine established their five-year partnership to develop clinical iPSC research at Kobe, which marks the site of human iPSC transplantation. This is not a symbolic MoU. It is a structured, outcomes driven partnership aimed at building real global infrastructure around iPSC based therapies.
ISCT brings three decades of experience translating cell and gene therapy research into clinical reality. JSRM brings direct translational leadership, including the world’s first clinical application of iPSC derived cells. The alignment is deliberate. The goal is to move from isolated breakthroughs to scalable, accessible therapies.
The collaboration will start conducting joint sessions at the 25th JSRM Annual Meeting which will alternate between the annual meetings of both societies. The process will identify operational delays which need urgent attention while executing solutions and tracking their success.
こちらもお読みください： トータルブレインケア、城南進学研究社と提携
The agenda is broad but focused. Improve trial design and multinational networks. Set global safety standards and integrate AI and automation into manufacturing. Push regulatory innovation without compromising patient safety. Align approval pathways across jurisdictions. Expand training across research, manufacturing, policy, and advocacy. Strengthen reimbursement models and medical affairs engagement.
The message is clear. Clinical iPSCs will not scale on science alone. They need coordination, standards, and policy alignment. This partnership is built to force that alignment into motion.
日本語